3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Prostatic Neoplasms
8
Neoplasms
4
Colorectal Neoplasms
4
Breast Neoplasms
3
Small Cell Lung Carcinoma
2
Rectal Neoplasms
2
Precancerous Conditions
2
Male Urogenital Diseases
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Cardiovascular Diseases
2
Vascular Diseases
1
Thrombocytopenia
1
Stomatitis
1
Squamous Cell Carcinoma of Head and Neck
1
Radiation Injuries
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Polycystic Ovary Syndrome
1
Ovarian Neoplasms
1
Non-melanoma Skin Cancer
1
Neurotoxicity Syndromes
1
Myocardial Ischemia
1
Myocardial Infarction
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphedema
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
Amifostine
12
Cisplatin
10
Radiotherapy
8
Etoposide
8
Cyclophosphamide
5
Paclitaxel
4
Filgrastim
4
Gemcitabine
3
Cytarabine
3
Carboplatin
3
denileukin diftitox
2
apatinib
2
Vincristine
2
Pyridoxine
2
Irinotecan
2
Ifosfamide
2
Fibroblast Growth Factor 7
2
Epoetin Alfa
2
Doxorubicin
2
Dexamethasone
2
Chemotherapy, Adjuvant
2
Bleomycin
2
uridine triacetate
1
sargramostim
1
peginterferon alfa-2b
1
pegfilgrastim
1
pegaspargase
1
eribulin
1
camrelizumab
1
Vitamin E
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Drug-Related Side Effects and Adverse Reactions
×
Vitamin E
×
Clear all
NCT00002586
2020-05-15
13-Cis
University of Colorado, Denver
Phase 2
Completed
96 enrolled